Skip to search formSkip to main contentSkip to account menu

Saquinavir

Known as: SQV, Saquinavir [Chemical/Ingredient], Saquinivir 
An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases… 
National Institutes of Health

Related topics

Related topics

34 relations
Acquired Immunodeficiency SyndromeAstemizoleCYP3A7 protein, humanDrug Allergy

Broader (6)

Antiviral AgentsCytochrome P-450 CYP3A InhibitorsHIV Protease InhibitorsIsoquinolines

Narrower (3)

Inviraseascorbyl-succinic-saquinavirsaquinavir-NO

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors
Accurate prediction of the extent of mechanism-based CYP3A inhibition is critical in determining the timing of clinical drug… 
Highly Cited
2009
Highly Cited
2009
On-line desorption of dried blood spot: A novel approach for the direct LC/MS analysis of micro-whole blood samples.
Highly Cited
2003
Highly Cited
2003
Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.
Highly Cited
2003
Highly Cited
2003
Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry.
  • K. Rentsch
  • Journal of chromatography. B, Analytical…
  • 2003
  • Corpus ID: 25390585
Highly Cited
2001
Highly Cited
2001
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
The low oral bioavailability of the HIV protease inhibitor (HPI) saquinavir is dramatically increased by coadministration of the… 
Highly Cited
1999
Highly Cited
1999
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
OBJECTIVES The effectiveness of a second protease inhibitor in patients who failed an initial protease inhibitor is unclear but… 
Highly Cited
1999
Highly Cited
1999
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
OBJECTIVE To determine whether baseline drug resistance assays could help to predict treatment failure with the protease… 
Highly Cited
1999
Highly Cited
1999
Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial.
OBJECTIVES To compare the efficacy and safety of indinavir 800 mg three times a day, ritonavir 600 mg twice a day, and a… 
Highly Cited
1998
Highly Cited
1998
Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.
Inhibiting human immunodeficiency virus (HIV) replication with potent antiretroviral therapy may result in improved immune… 
Highly Cited
1997
Highly Cited
1997
Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir
Objective:To assess the safety, efficacy and plasma drug levels of the combination of ritonavir plus saquinavir for the treatment… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)